Vita Coco Encounters Legal and Financial Challenges—Will Its Premium Status Hold Up?

Vita Coco Stock Plummets Amid Fraud Investigation and Revenue Concerns

Vita Coco shares recently plunged to a new 52-week low, triggered by two major developments: the launch of a formal fraud investigation and the looming threat of a significant revenue decline. The downturn began in late March 2026, with the stock dropping $5.26 per share, or roughly 9%, falling from $58.14 on March 17 to $52.88 on March 20. This sharp move followed renewed attention to a negative report from NINGI Research, which, despite being released a year earlier, resurfaced and rattled investors.

The central issue is a fraud investigation initiated on March 26, 2026 by Pomerantz Law Firm. The probe focuses on allegations of securities fraud and misleading growth statements, largely stemming from the NINGI Research report dated March 26, 2025. The report accuses Vita Coco of providing false information to investors, with the most damaging claim being the potential loss of a crucial contract with Costco—its largest private-label partner—even after a renewal in 2023. The report estimated that losing this contract could result in a $90 million revenue gap for Vita Coco by the end of 2025.

Investors are now left to determine whether the current stock price reflects an overreaction or a fundamental shift in the company's outlook. The investigation brings both legal and reputational challenges, while the anticipated $90 million revenue loss poses a real and immediate financial threat. For a company already trading at a discount, these developments force a reassessment of Vita Coco’s growth prospects and business credibility.

Assessing the $90 Million Revenue Threat

The projected $90 million revenue shortfall is substantial, but its true impact depends on the company’s overall size and valuation. This figure amounts to about 17.4% of Vita Coco’s 2024 revenue of $516 million. While this is a significant setback for a business with a market capitalization near $3.2 billion, it is not catastrophic. The key question is whether this loss undermines the growth story that justifies the stock’s premium valuation.

The stock’s recent price, hovering near its 52-week low, highlights the market’s heightened sensitivity. Over the past year, shares have ranged from a low of $25.79 to a high of $61.39, with the current price sitting about 51% below its peak. This volatility suggests that investors are pricing in risks beyond a single contract loss, likely reflecting broader concerns about the company’s future.

Valuation metrics further illustrate the challenge. With shares trading at approximately 47 times earnings, Vita Coco must sustain robust growth to support its current price. The market’s confidence has already waned, as the stock’s year-to-date gains have slowed to 55% after several years of strong performance. Any sign of slower growth—especially in light of the $90 million risk—could prompt a further downward adjustment in valuation, making this more than just a one-off financial setback.

In summary, the potential loss of the Costco contract is a significant near-term obstacle. For Vita Coco to maintain its valuation, the company must prove it can continue to grow even after absorbing this hit. While the investigation adds uncertainty, the real battle is about sustaining growth, not survival.

Upcoming Catalysts and Key Risks

The company’s immediate outlook depends on two critical events that could either ease investor fears or intensify them. The first is Vita Coco’s official response to the fraud investigation. As of now, the company has not issued a public statement regarding the Pomerantz Law Firm’s probe. A transparent and direct response—especially addressing the alleged loss of the Costco contract—could help restore confidence and reduce legal uncertainty. On the other hand, continued silence or a defensive stance may only heighten speculation and keep downward pressure on the stock.

The second major event is the release of the Q1 2026 earnings report, expected in late April or early May. This report will offer the first official insight into the impact of the alleged $90 million revenue shortfall. Investors will be watching closely for management’s comments on the status of the Costco contract and the company’s overall growth outlook. Analysts are currently forecasting continued mid-teens growth for 2026, so any deviation or confirmation of the contract loss could directly challenge the narrative supporting the stock’s valuation.

The biggest risk is that the fraud allegations gain momentum. The Pomerantz investigation follows a similar inquiry by Levi & Korsinsky. Should these probes result in a certified class-action lawsuit, Vita Coco could face prolonged legal uncertainty, limiting the stock’s upside for months. Recent reminders from the Schall Law Firm about class actions in the sector highlight the ongoing legal risks companies like Vita Coco face.

Ultimately, the stock’s next direction hinges on these upcoming catalysts. A strong, credible response and reassuring Q1 guidance could trigger a rebound from current lows. However, if the company fails to address the investigation or confirms the revenue loss, further declines are likely as valuation multiples compress and legal concerns persist. For now, investors are in a holding pattern, awaiting clarity on these pivotal issues.